Related references
Note: Only part of the references are listed.Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimer's disease
Erik Portelius et al.
BRAIN (2015)
Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis
Jens Kuhle et al.
NEUROLOGY (2015)
Neurogranin as a Cerebrospinal Fluid Biomarker for Synaptic Loss in Symptomatic Alzheimer Disease
Maartje I. Kester et al.
JAMA NEUROLOGY (2015)
CSF levels of YKL-40 are increased in MS and replaces with immunosuppressive treatment
Clas Malmestrom et al.
JOURNAL OF NEUROIMMUNOLOGY (2014)
Cell-selective knockout and 3D confocal image analysis reveals separate roles for astrocyte-and endothelial-derived CCL2 in neuroinflammation
Debayon Paul et al.
JOURNAL OF NEUROINFLAMMATION (2014)
Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial
Peter A. Calabresi et al.
LANCET NEUROLOGY (2014)
Immunosuppressive therapy reduces axonal damage in progressive multiple sclerosis
Markus Axelsson et al.
MULTIPLE SCLEROSIS JOURNAL (2014)
Effect of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod vs. interferon β-1 a intramuscular: Subgroup analyses of the Trial Assessing Injectable Interferon vs. Fingolimod Oral in Relapsing-Remitting Multiple Sclerosis (TRANSFORMS)
B. O. Khatri et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2014)
Relationship between Cerebrospinal Fluid Biomarkers for Inflammation, Demyelination and Neurodegeneration in Acute Optic Neuritis
Signe Modvig et al.
PLOS ONE (2013)
Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study
Virginia Devonshire et al.
LANCET NEUROLOGY (2012)
Axonal Damage in Relapsing Multiple Sclerosis is Markedly Reduced by Natalizumab
Martin Gunnarsson et al.
ANNALS OF NEUROLOGY (2011)
Diagnostic Criteria for Multiple Sclerosis: 2010 Revisions to the McDonald Criteria
Chris H. Polman et al.
ANNALS OF NEUROLOGY (2011)
Glial fibrillary acidic protein: a potential biomarker for progression in multiple sclerosis
M. Axelsson et al.
JOURNAL OF NEUROLOGY (2011)
Cerebrospinal fluid CXCL13 in multiple sclerosis: a suggestive prognostic marker for the disease course
Mohsen Khademi et al.
MULTIPLE SCLEROSIS JOURNAL (2011)
Increased cerebrospinal fluid chitotriosidase index in patients with multiple sclerosis
M. M. Verbeek et al.
ACTA NEUROLOGICA SCANDINAVICA (2010)
Fingolimod (FTY720) Enhances Remyelination Following Demyelination of Organotypic Cerebellar Slices
Veronique E. Miron et al.
AMERICAN JOURNAL OF PATHOLOGY (2010)
Cerebrospinal fluid chitinase 3-like 1 levels are associated with conversion to multiple sclerosis
Manuel Comabella et al.
BRAIN (2010)
Neurogranin in cerebrospinal fluid as a marker of synaptic degeneration in Alzheimer's disease
Annika Thorsell et al.
BRAIN RESEARCH (2010)
The role of monocyte chemoattractant protein MCP1/CCL2 in neuroinflammatory diseases
Gregory Conductier et al.
JOURNAL OF NEUROIMMUNOLOGY (2010)
Th17 central memory T cells are reduced by FTY720 in patients with multiple sclerosis
M. Mehling et al.
NEUROLOGY (2010)
Increased cerebrospinal fluid concentrations of the chemokine CXCL13 in active MS
F. Sellebjerg et al.
NEUROLOGY (2009)
A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking
C. E. Teunissen et al.
NEUROLOGY (2009)
IL-6 and CCL2 levels in CSF are associated with the clinical course of MS: Implications for their possible immunopathogenic roles
C. Malmestrom et al.
JOURNAL OF NEUROIMMUNOLOGY (2006)
Multiple sclerosis severity score -: Using disability and disease duration to rate disease severity
RHSR Roxburgh et al.
NEUROLOGY (2005)
Neurofilament light protein and glial fibrillary acidic protein as biological markers in MS
C Malmeström et al.
NEUROLOGY (2003)
The role of MCP-1 (CCL2) and CCR2 in multiple sclerosis and experimental autoimmune encephalomyelitis (EAE)
DJ Mahad et al.
SEMINARS IN IMMUNOLOGY (2003)
Recommended diagnostic criteria for multiple sclerosis: Guidelines from the International Panel on the Diagnosis of Multiple Sclerosis
WI McDonald et al.
ANNALS OF NEUROLOGY (2001)
Serum and CSF levels of MCP-1 and IP-10 in multiple sclerosis patients with acute and stable disease and undergoing immunomodulatory therapies
D Franciotta et al.
JOURNAL OF NEUROIMMUNOLOGY (2001)
Share Paper
